S&P 500
5,940.46
-0.4%
-23.14
DJI
42,677.24
-0.3%
-114.83
NASDAQ
$19,142.71
-0.4%
-$72.75
Bitcoin
107,568.00
+1.2%
+1,242.12
AAPL
$206.73
-1.0%
-$2.05
AMZN
$204.08
-1.0%
-$2.08
GOOG
$165.14
-1.6%
-$2.73
META
$636.43
-0.6%
-$4.00
MSFT
$457.90
-0.2%
-$0.97
NVDA
$134.22
-1.0%
-$1.34
TSLA
$343.52
+0.4%
+$1.43
vTv Therapeutics (NASDAQ: VTVT)
$20.49
(-3.6%)
-$0.76
Price as of May 20, 2025, 2:21 p.m. ET
vTv Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
vTv Therapeutics Company Info
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.